Lucid Diagnostics Inc
NASDAQ:LUCD
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.7643
1.65
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Lucid Diagnostics Inc
EPS (Diluted)
Lucid Diagnostics Inc
EPS (Diluted) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | EPS (Diluted) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
L
|
Lucid Diagnostics Inc
NASDAQ:LUCD
|
EPS (Diluted)
-$1
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-54%
|
CAGR 10-Years
N/A
|
|
|
Becton Dickinson and Co
NYSE:BDX
|
EPS (Diluted)
$5
|
CAGR 3-Years
0%
|
CAGR 5-Years
17%
|
CAGR 10-Years
6%
|
|
|
Boston Scientific Corp
NYSE:BSX
|
EPS (Diluted)
$1
|
CAGR 3-Years
64%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
N/A
|
|
|
Stryker Corp
NYSE:SYK
|
EPS (Diluted)
$7
|
CAGR 3-Years
6%
|
CAGR 5-Years
10%
|
CAGR 10-Years
9%
|
|
|
Abbott Laboratories
NYSE:ABT
|
EPS (Diluted)
$8
|
CAGR 3-Years
21%
|
CAGR 5-Years
34%
|
CAGR 10-Years
10%
|
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
EPS (Diluted)
$7
|
CAGR 3-Years
26%
|
CAGR 5-Years
21%
|
CAGR 10-Years
17%
|
|
Lucid Diagnostics Inc
Glance View
Lucid Diagnostics, Inc. develops medical testing devices. The company is headquartered in New York City, New York. The company went IPO on 2021-10-14. The firm is focused on patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux or reflux, that leads to esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma (EAC). Its products include EsoCheck and EsoGuard. EsoCheck is a noninvasive swallowable balloon capsule catheter device capable of sampling surface esophageal cells in an office procedure. The company consists of a vitamin pill-sized rigid plastic capsule tethered to a thin silicone catheter from which a soft silicone balloon with textured ridges emerges to swab surface esophageal cells. EsoGuard is a bisulfite-converted next generation sequencing (NGS) deoxyribonucleic acid (DNA) assay performed on surface esophageal cells collected with EsoCheck. The firm is a subsidiary of PAVmed Inc.
See Also
What is Lucid Diagnostics Inc's EPS (Diluted)?
EPS (Diluted)
-1.1
USD
Based on the financial report for Dec 31, 2024, Lucid Diagnostics Inc's EPS (Diluted) amounts to -1.1 USD.
What is Lucid Diagnostics Inc's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 5Y
-54%
Over the last year, the EPS (Diluted) growth was 17%. The average annual EPS (Diluted) growth rates for Lucid Diagnostics Inc have been -9% over the past three years , -54% over the past five years .